← board
ODYY
distress 6/10 · elevated risk$0.010%today-94% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
0.8 yrs
Shares 1y
+1%
Price & events
-90.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-14.3%
1W
-40.0%
1M
-91.7%
3M
-90.5%
6M
-76.9%
1Y
-89.1%
2Y
-98.9%
5Y
-97.8%
All
Overview
- Market Cap
- $605.81K
- Volume
- 3.70K
- 52 Week Range
- $0.01 – $0.10
- Total Shares
- 100.97M
- Float Shares
- 85.13M
- % Held by Insiders
- 15.69%
- % Held by Institutions
- 0.00%
- RVOL
- 0.02x
- Beta
- -1.46
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 2
- 2026-04-21partnershipBreastCheck · Exclusive worldwide marketing and distribution rights granted to Odyssey Medical Devices for BreastCheck.SEC 8-K
- 2025-10-14partnershipBreastCheck · Exclusive worldwide sub-license for non-invasive breast abnormality test from NeuRX Health.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.